Global Acne Drugs Market 2016-2020

2015-11-18
Price :
Published : Nov-2015
No. of Pages : 84

Global Acne Drugs Market 2016-2020

Covering: This market research report presents a detailed segmentation of the global acne drugs market by drug class (antibiotics, anti-inflammatory drugs, antimicrobial, combination medications, hormonal agents, oral retinoid, and topical retinoid), by route of administration (topical, and oral), and by type (prescription and OTC). It outlines the market shares for key regions such as the Americas, APAC, and EMEA. The key vendors analyzed in this report are Allergan, Galderma, Stiefel, and Valeant.

Market outlook of acne drugs

The market research analyst predicts the global acne drugs market to grow steadily at a CAGR of approximately 3% during the forecast period. The occurrence of acne due to lifestyle changes is the primary driver for the market. Sedentary lifestyle and unhealthy food habits lead to hormonal problems, which trigger the development of acne. Lack of sleep, emotional and work-related stress, smoking, drug abuse, and alcohol consumption are major triggers for the occurrence of acne among teenagers and adults.

The rise in disposable income has encouraged consumers, especially the middle-class income group, to spend more on personal care products. The rising awareness of acne and the current and upcoming treatments is expected to drive the acne drugs market through the forecast period. Women particularly, play a crucial role in this market as the demand generated by them influences the market growth considerably.

Segmentation by drug class and analysis of the acne drugs market

  • Antibiotics
  • Anti-inflammatory drugs
  • Antimicrobial
  • Combination medications
  • Hormonal agents
  • Oral retinoid
  • Topical retinoid

Acne medication depends on the skin type and the severity of the condition. For instance, oral retinoid agents are considered as the appropriate treatment for severe acne. These drugs help prevent excessive oil production, bacterial acne growth, and inflammation.

Segmentation by method of administration and analysis of the acne drugs market

  • Topical
  • Oral

The topical drugs segment dominated the market during 2015, accounting for a market share of around 54%. Ease of application, low systemic side-effects, and easy availability of these products are the primary drivers for the growth of this segment.

Segmentation by type and analysis of the acne drugs market

  • Prescription drugs
  • OTC drugs

Prescription drugs dominated the market during 2015 due to the increased awareness about acne and the treatments options, especially in the developed countries. For instance, Epiduo, Benzaclin, and Duac are some of the popular acne prescription drugs available in the market.

Segmentation by geography and analysis of the acne drugs market

  • Americas
  • APAC
  • EMEA

The Americas accounted for around 90% of the market share during 2015 but is expected to witness a decline in sales during the forecast period. Lifestyle changes, increase in awareness programs about acne, and availability of acne treatment options are the primary drivers for market growth in this region.

Competitive landscape and key vendors

The global acne drugs market is dominated by key vendors. The availability of OTC drugs and the preference for alternative therapies for treating acne has been restricting the sales of branded acne products. Vendors in this market are anticipated to invest heavily on R&D during the forecast period.

The leading vendors in the market are -

  • Allergan
  • Galderma
  • Stiefel
  • Valeant

The other prominent vendors in the market include AndroScience, Anterios, Aqua Pharmaceuticals, Astellas, Bayer HealthCare, BioPharmX, Celtaxsys, Cipher Pharmaceuticals, COSMO Pharmaceuticals, Dermira, Elorac, F.Hoffmann-La Roche, Foamix, GlaxoSmithKline, Guthy-Renker, Helix BioMedix, Hygeia Therapeutics, Johnson & Johnson, Meda, Mylan, Novan, Oculus Innovative Sciences, Paratek Pharmaceuticals, Photocure, Promius Pharma, Ranbaxy, Reckitt Benckiser, Skinvisible Pharmaceuticals, Teva, Versapharm, and XBiotech.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the global acne drugs market
  • What are the key market trends impacting the growth of the acne drugs market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the global acne drugs market
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA
  • What are the key outcomes of the five forces analysis of the acne drugs market
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026 Summary Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Sta......
$3995

EpiCast Report: Epilepsy – Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026 Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014). In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% pe......
$3995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina Summary Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021. Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report p......
$1000

EpiCast Report: Melanoma – Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013). In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagn......
$3995

EpiCast Report: Crohn’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel. Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 a......
$3995

Hyperkalemia Global Clinical Trials Review, H2, 2017

Hyperkalemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperkalemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperkalemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperkalemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Hyperalgesia Global Clinical Trials Review, H2, 2017

Hyperalgesia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperalgesia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperalgesia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperalgesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Hyperlipidemia Global Clinical Trials Review, H2, 2017

Hyperlipidemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperlipidemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperlipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperlipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hyperammonemia Global Clinical Trials Review, H2, 2017

Hyperammonemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperammonemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperammonemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperammonemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500